ROCKAWAY, NJ , Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference .
ROCKAWAY, NJ , Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC . (Red One). The partnership will further expand availability of electroCore’s gammaCore
ROCKAWAY, NJ , Aug. 10, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, “Transcutaneous Cervical Vagal Nerve Stimulation (tcVNS/nVNS) in Patients with Posttraumatic Stress
Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET ROCKAWAY, NJ , Aug. 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc.
ROCKAWAY, NJ , Aug. 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled “gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance” in the journal
ROCKAWAY, NJ , Aug. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation and be available for virtual one-on-one meetings at the Canaccord
ROCKAWAY, NJ , July 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile
ROCKAWAY, NJ , July 22, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021 .
ROCKAWAY, NJ , July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats , is to receive a Lifetime Achievement Award at the American Society
Second-Quarter 2021 revenue expected to be approximately $ 1.3 million Net cash used to fund operations in the second quarter 2021 of approximately $ 3.2 million Follow on offering subsequent to June 30, 2021 added $18 . 8 million to cash balance ROCKAWAY, NJ , July 13, 2021 (GLOBE NEWSWIRE)